Lexeo Therapeutics, Inc. (LXEO) Stock Forecast & Price Target

Compare

286 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

LXEO Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Lexeo

Therapeutics, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

LXEO Stock 12 Month Forecast

Average Price Target

$18.00

▲(170.27% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Lexeo Therapeutics, Inc. in the last 3 months. The average price target is $18.00 with a high forecast of $25.00 and a low forecast of $10.00. The average price target represents a 170.27% change from the last price of $6.66.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","7.25":"$7.25","13.5":"$13.5","19.75":"$19.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7.25,13.5,19.75,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jul<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.64,8.975384615384614,10.31076923076923,11.646153846153846,12.981538461538461,14.316923076923077,15.65230769230769,16.987692307692306,18.323076923076922,19.658461538461538,20.993846153846153,22.32923076923077,23.664615384615384,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.64,8.436923076923076,9.233846153846153,10.03076923076923,10.827692307692306,11.624615384615383,12.42153846153846,13.218461538461536,14.015384615384615,14.81230769230769,15.609230769230768,16.406153846153845,17.20307692307692,{"y":18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.64,7.821538461538461,8.003076923076923,8.184615384615384,8.366153846153846,8.547692307692307,8.72923076923077,8.91076923076923,9.092307692307692,9.273846153846154,9.455384615384615,9.636923076923077,9.818461538461538,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.41,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.58,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.61,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.01,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.92,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.93,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.64,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$18.00

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kristen Kluska

Cantor Fitzgerald

$19

Buy

185.29%

Upside

Reiterated

02/25/26

Cantor Fitzgerald Remains a Buy on Lexeo Therapeutics, Inc. (LXEO)

Mitchell Kapoor

H.C. Wainwright

$13→$10

Buy

50.15%

Upside

Reiterated

01/13/26

Lexeo Therapeutics price target lowered to $10 from $13 at H.C. WainwrightLexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright

Christopher Raymond

Raymond James

$10.54→$25

Buy

275.38%

Upside

Reiterated

01/13/26

Raymond James Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)

Geulah Livshits

Chardan Capital

$17

Buy

155.26%

Upside

Reiterated

11/05/25

Analysts' Top Healthcare Picks: Lexeo Therapeutics, Inc. (LXEO), Dianthus Therapeutics (DNTH)

Luca Issi

RBC Capital

$20

Buy

200.30%

Upside

Reiterated

11/05/25

Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from RBC Capital

Mani Foroohar

Leerink Partners

$20→$18

Buy

170.27%

Upside

Reiterated

10/21/25

Lexeo Therapeutics price target lowered to $18 from $20 at LeerinkLexeo Therapeutics price target lowered to $18 from $20 at Leerink

Debjit Chattopadhyay

Guggenheim

$30

Buy

350.45%

Upside

Initiated

10/15/25

Lexeo Therapeutics initiated with a Buy at GuggenheimLexeo Therapeutics initiated with a Buy at Guggenheim

Leland Gershell

Oppenheimer

$20

Buy

200.30%

Upside

Reiterated

10/08/25

Lexeo Therapeutics, Inc. (LXEO) Receives a Buy from Oppenheimer

Tessa Romero

J.P. Morgan

―

Buy

―

Reiterated

10/07/25

Buy Rating for Lexeo Therapeutics Driven by Regulatory Progress and Promising Clinical Data on LX2006

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kristen Kluska

Cantor Fitzgerald

$19

Buy

185.29%

Upside

Reiterated

02/25/26

Cantor Fitzgerald Remains a Buy on Lexeo Therapeutics, Inc. (LXEO)

Mitchell Kapoor

H.C. Wainwright

$13→$10

Buy

50.15%

Upside

Reiterated

01/13/26

Lexeo Therapeutics price target lowered to $10 from $13 at H.C. WainwrightLexeo Therapeutics price target lowered to $10 from $13 at H.C. Wainwright

Christopher Raymond

Raymond James

$10.54→$25

Buy

275.38%

Upside

Reiterated

01/13/26

Raymond James Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)

Geulah Livshits

Chardan Capital

$17

Buy

155.26%

Upside

Reiterated

11/05/25

Analysts' Top Healthcare Picks: Lexeo Therapeutics, Inc. (LXEO), Dianthus Therapeutics (DNTH)

Luca Issi

RBC Capital

$20

Buy

200.30%

Upside

Reiterated

11/05/25

Lexeo Therapeutics, Inc. (LXEO) Gets a Buy from RBC Capital

Mani Foroohar

Leerink Partners

$20→$18

Buy

170.27%

Upside

Reiterated

10/21/25

Lexeo Therapeutics price target lowered to $18 from $20 at LeerinkLexeo Therapeutics price target lowered to $18 from $20 at Leerink

Debjit Chattopadhyay

Guggenheim

$30

Buy

350.45%

Upside

Initiated

10/15/25

Lexeo Therapeutics initiated with a Buy at GuggenheimLexeo Therapeutics initiated with a Buy at Guggenheim

Leland Gershell

Oppenheimer

$20

Buy

200.30%

Upside

Reiterated

10/08/25

Lexeo Therapeutics, Inc. (LXEO) Receives a Buy from Oppenheimer

Tessa Romero

J.P. Morgan

―

Buy

―

Reiterated

10/07/25

Buy Rating for Lexeo Therapeutics Driven by Regulatory Progress and Promising Clinical Data on LX2006

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Lexeo Therapeutics, Inc.

3 Months

xxx

Success Rate

8/14 ratings generated profit

Average Return

+18.63%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +18.63% per trade.

1 Year

Mitchell KapoorH.C. Wainwright

Success Rate

6/12 ratings generated profit

Average Return

+13.53%

reiterated a buy rating 2 months ago

Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +13.53% per trade.

2 Years

xxx

Success Rate

4/11 ratings generated profit

Average Return

+5.44%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 36.36% of your transactions generating a profit, with an average return of +5.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LXEO Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, LXEO has received 7 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. LXEO average Analyst price target in the past 3 months is 18.00.

Each month's total comprises the sum of three months' worth of ratings.

LXEO Financial Forecast

LXEO Earnings Forecast

Currently, no earnings data available.

No data currently available

LXEO Sales Forecast

Currently, no sales data available.

LXEO Stock Forecast FAQ

What is LXEO’s average 12-month price target, according to analysts?

Based on analyst ratings, Lexeo Therapeutics, Inc.’s 12-month average price target is 18.00.

What is LXEO’s upside potential, based on the analysts’ average price target?

Lexeo Therapeutics, Inc. has 170.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is LXEO a Buy, Sell or Hold?

Lexeo Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Lexeo Therapeutics, Inc.’s price target?

The average price target for Lexeo Therapeutics, Inc. is 18.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $10.00. The average price target represents 170.27% Increase from the current price of $6.66.

What do analysts say about Lexeo Therapeutics, Inc.?

Lexeo Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of LXEO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Lexeo Therapeutics, Inc. (LXEO) Stock Forecast & Price Target

LXEO Analyst Ratings

LXEO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Lexeo Therapeutics, Inc.

LXEO Analyst Recommendation Trends

LXEO Financial Forecast

LXEO Earnings Forecast

LXEO Sales Forecast

LXEO Stock Forecast FAQ

Detailed List of Analyst Forecasts